NCT02111317已完成1 期
A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of ASP015K: Maximum concentration (Cmax)
研究概览
简要总结
The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.
详细描述
Eligible subjects will be admitted to the clinical unit on day -1 and remain confined until day 15.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must weigh at least 50 kg
- •Subject must be capable of swallowing multiple tablets
- •Subject agrees not to participate in another investigational study while on treatment
排除标准
- •Subject has a known or suspected hypersensitivity to verapamil, ASP015K, or any components of the formulations used.
- •Subject has any of the liver function tests above the upper limit of normal (ULN)
- •Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- •Subject has any history or evidence of any clinically significant cardiovascular, GI, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy
- •Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory) infection, or fungal (noncutaneous) infection within 1 week prior to day -
- •Subject has any clinically significant abnormality following physical examination, ECG, such as sick sinus syndrome, second- or third-degree atrioventricular block, or atrial flutter/atrial fibrillation, or clinical laboratory tests
- •Subject has a mean pulse < 50 or > 90 beats per minute (bpm); mean systolic blood pressure (SBP) < 100 or > 140 mmHg; mean diastolic blood pressure (DBP) < 60 or > 90 mmHg (measurements taken in triplicate after subject has been resting in sitting position for 5 minutes)
- •Subject has a mean QTcF interval of > 430 msec (for males) and > 450 msec (for females)
- •Subject has used any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, with the exception of hormone replacement therapy (HRT) and intermittent acetaminophen (no more than 2 g per day)
- •Subject has smoked or has used tobacco-containing products and nicotine or nicotine-containing products in the past 6 months
- •Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits)
- •Subject has a positive test for alcohol, drugs of abuse, or cotinine
- •Subject anticipates an inability to abstain from xanthine (e.g., caffeine), grapefruit, Seville oranges (including marmalade), star fruit, or any products containing these items from 72 hours prior to day -1 and throughout the duration of the study
- •Subject has used any inducer of metabolism (e.g., barbiturates, rifampin) in the past 3 months prior to day -1
- •Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within past 7 days
- •Subject has a positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (Immunoglobulin [Ig] M), anti-hepatitis C virus (HCV), hepatitis B core antibody or anti-human immunodeficiency virus (HIV) type 1 or type 2
- •Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold® test or T-SPOT® test
- •Subject received any vaccine within 60 days prior to study drug administration
- •Subject has an absolute neutrophil count (ANC) < 2000 cells/mm3 or a creatine phosphokinase (CPK) > 1.5 x ULN
- •Subject has had major gastrointestinal (GI) surgery or has a medical condition, which may inhibit the absorption and/or metabolism of study drug
- •Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives of the drug, whichever is longer
研究组 & 干预措施
ASP015K and verapamil
Experimental
Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
干预措施: ASP015K (Drug)
ASP015K and verapamil
Experimental
Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
干预措施: verapamil (Drug)
结局指标
主要结局
Pharmacokinetics of ASP015K: Maximum concentration (Cmax)
时间窗: Days 1-4 and Days 12-15
Pharmacokinetics of ASP015K: Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration (AUClast)
时间窗: Days 1-4 and Days 12-15
Pharmacokinetics of ASP015K: AUC from the time of dosing extrapolated to time infinity (AUCinf)
时间窗: Days 1-4 and Days 12-15
次要结局
- Pharmacokinetic profile of ASP015K: time of maximum plasma concentration (tmax), terminal elimination half-life (t½), apparent total systemic clearance (CL/F), and apparent volume of distribution during the terminal elimination phase (Vz/F)(Days 1-4 and Days 12-15)
- Pharmacokinetic profile of ASP015K metabolites: Cmax, AUClast, AUCinf, tmax and t½(Days 1-4 and Days 12-15)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female VolunteersHealthyNCT02171533Boehringer Ingelheim40
已完成
1 期
A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination TabletDrug-Drug Interaction (DDI)Healthy SubjectsNCT01943487Astellas Pharma Europe B.V.36
进行中（未招募）
1 期
P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-releasehealthy volunteersEUCTR2020-001655-41-FRCHU de Rennes28
招募中
3 期
Effect of verapamil on sitagliptin efficacy in diabetesIRCT20180417039339N1Ahvaz University of Medical Sciences46
已完成
2 期
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerLung NeoplasmsOvarian NeoplasmsCervix NeoplasmsRenal NeoplasmsNCT00069160National Cancer Institute (NCI)48